Nivolumab — Drug Intelligence | 200 EU Trials

Filter these 200 trials by condition, phase, country and more.

Open in Search →

200 Registered trials

71 Recruiting

108 Completed trials

104 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 56 Phase II/III: 10 Phase II: 78 Phase I/II: 26 Phase IV: 11 Phase I (Other): 2 Phase I (FiH): 17

Oversight events:

5 serious breaches 12 temporary halts 2 urgent safety measures 1 unexpected event across 9 trials

View oversight register →

Indications tested

Non-small cell lung cancer 11 Hepatocellular carcinoma 7 Gastric cancer 5 Bladder cancer 5 Renal cell carcinoma 5 Colorectal cancer 4 Uveal melanoma 4 Malignant melanoma stage III 4 Gastrooesophageal cancer 3 Head and neck cancer 3 Metastatic renal cell carcinoma 3 Malignant melanoma stage IV 3

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 22 Bristol Myers Squibb International Corporation 20 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 11 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 5 Institut Gustave Roussy 5 CatalYm GmbH 4 Fundacion GECP 4 Intergroupe Francophone De Cancerologie Thoracique 4 Unicancer 4 Centre Leon Berard 3 Exelixis Inc. 3 Karolinska University Hospital 3

All trials

200 total

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised

2023-506686-66-00 Phase II/III 1 country Ideaya Biosciences Inc.
Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo… Pending

2023-508658-24-00 Phase II 4 countries European Organisation For Research And Treatment Of Cancer
A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n… Pending

2023-508784-68-00 Phase II/III 5 countries Replimune Inc.
CHOPIN Pending

2024-516127-14-01 Phase I (FiH) 1 country Leids Universitair Medisch Centrum (LUMC)
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) Pending

2024-516718-39-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) Pending

2024-517378-22-00 Phase II 1 country Fondazione Centro Nazionale Di Adroterapia Oncologica
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Phase II 1 country Association Gercor
Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study Pending

2024-518545-13-00 Phase II 1 country Melanoma Institute Australia
IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hypertherm… Pending

2024-519626-21-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies Pending

2024-519812-15-00 Phase IV 1 country Centre Hospitalier Universitaire D'Angers
Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending

2024-520045-23-00 Phase II 1 country ARTIC
NOCANO: Nivolumab as neoadjuvant immunotherapy for patients with Oral CANcer and identification of response-predictive biomarkers in tumour … Pending

2025-521006-18-00 Phase II 1 country Karolinska University Hospital
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma w… Pending

2025-521437-88-00 Phase II 1 country Groupe Oncologie Radiotherapie Tete Cou
The MAYA2 trial Pending

2025-521941-25-00 Phase II 1 country Odense University Hospital
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1) Pending

2025-522944-41-00 Phase I (FiH) 2 countries Pathios Therapeutics Limited
A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer Pending

2025-524090-16-00 Phase I (FiH) 3 countries Bristol-Myers Squibb Services Unlimited Company
Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending

2025-524620-22-00 Phase I/II 4 countries Orion Corporation
COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vul… Pending

2025-524759-29-00 Phase I/II 1 country Centre Leon Berard
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending

2026-525263-41-00 Phase III 1 country Polska Grupa Badawcza Chloniakow
Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma Pending

2026-525267-40-00 Phase IV 1 country Centro Di Riferimento Oncologico Di Aviano
Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a… Recruiting

2025-520675-86-00 Phase II 4 countries CatalYm GmbH
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Phase III 7 countries Mabxience Research S.L.
Randomized phase 2 study of Simvastatin in patients with ARID1A mutated advanced gastrooesophageal carcinoma treated with Nivolumab and Oxal… Recruiting

2024-519591-39-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale

Showing 1–24 of 200 trials

← All drugs A–Z